Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04893785
Title A Phase II Single Arm Interventional Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM) (CABOTEM)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors National Cancer Institute, Naples

gastrointestinal neuroendocrine tumor

islet cell tumor

pulmonary neuroendocrine tumor


Cabozantinib + Temozolomide

Age Groups: adult | senior
Covered Countries ITA

No variant requirements are available.